Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate-to-severe plaque psoriasis in adults, receives health insurance benefits in Korea for treating adult patients with chr...
HUMIRA® (adalimumab) is a biologic for adults with moderate to severe chronic plaque psoriasis (PS). See Important Safety Info, including the BOXED WARNING.
Barcelona 18th September 2018 · Almirall, S.A. announced today that the European Commission(EC)has approved ILUMETRI® (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy1 . Roll out of ILUMETRI® (tildrakizumab) in Europe will start in the next few weeks. Germany will be the first country to launch the product. Tildrakizumab is a humanized high-affinity anti-IL-23p19 monoclonal antibody.1 Due to it ...
Semantic Scholar extracted view of "Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial" by H. Bachelez et al.
Read more about ENBREL® (etanercept) for patients, 4 years and older, with moderate to severe plaque psoriasis. See Full Prescribing & Safety Info.
Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. by M Inzinger, B Heschl, W Weger, A...
Summary Background Fumaric acid esters (FAEs) are recommended in international guidelines for induction and long-term treatment of adults with moderate-to-severe chronic plaque psoriasis. The fixed...
Providing real-world data on the long-term drug survival and effectiveness of secukinumab in patients with moderate to severe chronic plaque psoriasis
One phase II and two large phase IIIrandomized controlled trials (RCTs) of tildrakizumab have been conducted in patients with moderate-to-severe chronic plaque psoriasis. 6,9 Tildrakizumab...
The newest systemic treatment for plaque psoriasis is the interleukin-17A and interleukin-17F antagonist bimekizumab (Bimzelx). Bimzelx works by selectively and directly inhibiting both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines that drive the inflammatory process in plaque psoriasis. Another new treatment for plaque psoriasis is the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu). TYK2 inhibitors work by inhibiting TYK2, an intracellular signaling kinase that mediates signaling of IL-23, IL-12 and Typ ...